Jenburkt [JENBURPH] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison

Jenburkt

BSE
Loading...

Aarti Drugs

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Jenburkt wins in 14 metrics, Aarti Drugs wins in 6 metrics, with 0 ties. Jenburkt appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricJenburktAarti DrugsBetter
P/E Ratio (TTM)14.8923.66Jenburkt
Price-to-Book Ratio2.813.26Jenburkt
Debt-to-Equity Ratio2.2744.92Jenburkt
PEG Ratio2.910.37Aarti Drugs
EV/EBITDA11.8817.07Jenburkt
Profit Margin (TTM)20.97%7.80%Jenburkt
Operating Margin (TTM)23.18%10.11%Jenburkt
EBITDA Margin (TTM)23.18%10.11%Jenburkt
Return on Equity18.66%12.28%Jenburkt
Return on Assets (TTM)16.34%6.53%Jenburkt
Free Cash Flow (TTM)$81.92M$674.22MAarti Drugs
Dividend Yield2.48%0.22%Jenburkt
1-Year Return8.77%-5.48%Jenburkt
Price-to-Sales Ratio (TTM)3.121.84Aarti Drugs
Enterprise Value$4.67B$50.47BAarti Drugs
EV/Revenue Ratio3.022.08Aarti Drugs
Gross Profit Margin (TTM)81.65%36.77%Jenburkt
Revenue per Share (TTM)$351$265Jenburkt
Earnings per Share (Diluted)$73.46$20.63Jenburkt
Beta (Stock Volatility)0.380.12Aarti Drugs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Jenburkt vs Aarti Drugs Stock Performance Analysis

Loading Price Chart...

Jenburkt
Aarti Drugs
Jenburkt Stock Overview | Aarti Drugs Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Jenburkt-0.42%-1.85%-5.15%-20.20%5.78%-11.50%
Aarti Drugs0.20%-5.64%3.08%3.92%42.25%7.15%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Jenburkt8.77%96.74%188.92%120.06%1,195.02%2,298.67%
Aarti Drugs-5.48%-1.60%-50.42%217.00%2,669.86%2,850.73%

News Based Sentiment: Jenburkt vs Aarti Drugs

Jenburkt

News based Sentiment: MIXED

September presented a mixed bag for Jenburkt Pharmaceuticals, with positive year-over-year growth in revenue and profit countered by short-term declines and a negative market sentiment. The closure of the trading window signals an upcoming earnings release that will be pivotal in shaping the company's investment narrative.

View Jenburkt News Sentiment Analysis

Aarti Drugs

News based Sentiment: POSITIVE

Aarti Drugs reported substantial profit growth in both Q1FY26 and FY2025, coupled with increased institutional interest from Mutual Funds. While shareholding changes and recent price volatility exist, the overall narrative points towards a strengthening investment case.

View Aarti Drugs News Sentiment Analysis

Performance & Financial Health Analysis: Jenburkt vs Aarti Drugs

MetricJENBURPHAARTIDRUGS
Market Information
Market Cap i₹4.87B₹44.55B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i1,945201,942
90 Day Avg. Volume i1,278187,563
Last Close₹1,074.90₹489.05
52 Week Range₹936.70 - ₹1,410.00₹312.00 - ₹564.05
% from 52W High-23.77%-13.30%
All-Time High₹1,410.00 (Jul 08, 2025)₹1,026.95 (Oct 05, 2020)
% from All-Time High-23.77%-52.38%
Growth Metrics
Quarterly Revenue Growth0.09%0.06%
Quarterly Earnings Growth0.05%0.62%
Financial Health
Profit Margin (TTM) i0.21%0.08%
Operating Margin (TTM) i0.23%0.10%
Return on Equity (TTM) i0.19%0.12%
Debt to Equity (MRQ) i2.2744.92
Cash & Liquidity
Book Value per Share (MRQ)₹389.23₹149.84
Cash per Share (MRQ)₹52.44₹2.48
Operating Cash Flow (TTM) i₹252.79M₹2.83B
Levered Free Cash Flow (TTM) i₹320.61M₹1.68B
Dividends
Last 12-Month Dividend Yield i2.48%0.22%
Last 12-Month Dividend i₹33.30₹1.00

Valuation & Enterprise Metrics Analysis: Jenburkt vs Aarti Drugs

MetricJENBURPHAARTIDRUGS
Price Ratios
P/E Ratio (TTM) i14.8923.66
Forward P/E i31.3815.02
PEG Ratio i2.910.37
Price to Sales (TTM) i3.121.84
Price to Book (MRQ) i2.813.26
Market Capitalization
Market Capitalization i₹4.87B₹44.55B
Enterprise Value i₹4.67B₹50.47B
Enterprise Value Metrics
Enterprise to Revenue i3.022.08
Enterprise to EBITDA i11.8817.07
Risk & Other Metrics
Beta i0.380.12
Book Value per Share (MRQ) i₹389.23₹149.84

Financial Statements Comparison: Jenburkt vs Aarti Drugs

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)JENBURPHAARTIDRUGS
Revenue/Sales i₹355.27M₹5.91B
Cost of Goods Sold i₹65.18M₹3.73B
Gross Profit i₹290.09M₹2.17B
Research & Development iN/AN/A
Operating Income (EBIT) i₹82.35M₹593.60M
EBITDA i₹110.14M₹743.90M
Pre-Tax Income i₹101.82M₹511.10M
Income Tax i₹23.90M₹-28.60M
Net Income (Profit) i₹77.92M₹539.70M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)JENBURPHAARTIDRUGS
Cash & Equivalents i₹73.65M₹45.77M
Total Current Assets i₹565.32M₹13.38B
Total Current Liabilities i₹188.19M₹8.37B
Long-Term Debt i₹14.92M₹2.86B
Total Shareholders Equity i₹1.72B₹13.69B
Retained Earnings i₹1.62B₹12.40B
Property, Plant & Equipment i₹144.29M₹27.03M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)JENBURPHAARTIDRUGS
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricJENBURPHAARTIDRUGS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i1,945201,942
Average Daily Volume (90 Day) i1,278187,563
Shares Outstanding i4.41M91.27M
Float Shares i1.77M39.04M
% Held by Insiders i0.73%0.60%
% Held by Institutions i0.00%0.11%

Dividend Analysis & Yield Comparison: Jenburkt vs Aarti Drugs

MetricJENBURPHAARTIDRUGS
Last 12-Month Dividend i₹33.30₹1.00
Last 12-Month Dividend Yield i2.48%0.22%
3-Year Avg Annual Dividend i₹19.90₹1.00
3-Year Avg Dividend Yield i1.83%0.23%
3-Year Total Dividends i₹59.70₹3.00
Ex-Dividend DateJul 11, 2025Feb 04, 2025